Events Archives - Page 3 of 8 - Telix Pharmaceuticals Limited

Telix at ANZSNM Annual Scientific Meeting 2024

Telix today announces five oral abstract presentations featuring the Company’s late-stage theranostic programs at the 54th Annual Scientific Meeting of the Australian and New Zealand Society of Nuclear Medicine (ANZSNM ASM 2024), being held in Christchurch (New Zealand) from 26-28 April 2024.

TLX101-CDx (Pixclara™) Granted FDA Fast Track Designation

Telix today announces that the United States (U.S.) Food and Drug Administration (FDA) has granted Fast Track designation1 for the Company’s investigational glioma imaging product, TLX101-CDx (Pixclara™2, 18F-floretyrosine or 18F-FET).

TLX250-CDx (Zircaix®) Recognised in EAU Guidelines as an Emerging Technology for the Management of RCC (Kidney Cancer)

Telix today welcomes updated guidelines from the European Association of Urology (EAU) that for the first time include TLX250-CDx (Zircaix®, 89Zr-DFO-girentuximab) as an emerging technology for the management of renal cell carcinoma (RCC).

Telix Completes Acquisition of IsoTherapeutics

Telix today announces the completion of the acquisition of IsoTherapeutics. IsoTherapeutics is a privately held, commercial-stage company that provides radiochemistry and bioconjugation development and contract manufacturing services to numerous companies in the radiopharmaceutical industry, including Telix. The acquisition further enhances Telix’s in-house development capabilities and expands Telix’s United States (U.S.) manufacturing footprint with particular focus on bioconjugation and isotope processing.

Telix GM 2024

Telix's 2024 GM was held on Friday, 5th April 2024 at The Wesley Conference Centre in Sydney, Australia and online.

Telix to Present Phase III ProstACT GLOBAL Study (TLX591 Therapy) and Phase II STARBURST Study (TLX250-CDx Indication Expansion) at EAU

Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces presentations featuring the Company’s late-stage theranostic programs at the 39th Annual European Association of Urology Congress (EAU24), Europe’s largest urological event, being held in Paris (France) from 5-8 April 2024.

Phase II OPALESCENCE Study of TLX250-CDx in Triple Negative Breast Cancer to be Presented at SABCS

Telix today advises that the completed Phase II OPALESCENCE investigator-initiated trial (IIT) of its carbonic anhydrase IX (CAIX)-targeting positron emission tomography (PET) imaging candidate, TLX250-CDx (89Zr-DFO-girentuximab), in patients with triple-negative breast cancer (TNBC), will be presented at the 2023 San Antonio Breast Cancer Symposium® (SABCS) taking place from December 5-9, 2023.

Telix to Showcase New ZIRCON Phase III Kidney Cancer Imaging Data and Theranostic Pipeline at EANM

Telix today announces presentations featuring the Company’s theranostic programs at the 36th Annual Congress of the European Association of Nuclear Medicine (EANM) to be held in Vienna from 9 – 13 September 2023.

Join Telix at EANM 2023 to explore personalised diagnostics in urological cancers

New ZIRCON Phase III Data Presented at SNMMI: Potential Utility of TLX250-CDx in Staging and Monitoring ccRCC

today announces further details of the positive results from its completed pivotal Phase III ZIRCON study of TLX250-CDx (89Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC) (ClinicalTrials.gov Identifier: NCT03849118).